A Fatality Following Ingestion of the Designer Drug Meta-Chlorophenylpiperazine (mCPP) in an Asthmatic-HPLC-MS/MS Detection in Biofluids and Hair

Journal of Forensic Sciences

Volumn 58, Issue 1, 2013, Pages 263-269

  Gaillard, Yvan P ^a,b   Cuquel, Anne Claire ^a,b,c   Boucher, Alexandra ^d   Romeuf, Ludovic ^a,b   Bevalot, Fabien ^a,b   Prevosto, Jen Michel ^e   Menard, Jean Marie ^f  

^a Laboratory of Analytical Toxicology   (France)

^b LAT LUMTOX   (France)

^c Ecole du Service de Santé des Armées   (France)

^d Centre d'Evaluation et d'Information sur la Pharmacodépendance   (France)

^e HIA Desgenettes   (France)

^f Cabinet médical   (France)

Author keywords

Death; Forensic science; HPLC MS MS; Meta chlorophenylpiperazine (mCPP); Poisoning

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; 1-(3-CHLOROPHENYL)PIPERAZINE; DESIGNER DRUG; PIPERAZINE DERIVATIVE; SEROTONIN AGONIST;

ADULT; ARTICLE; ASTHMA; BILE; BRONCHUS; CASE REPORT; CHEMISTRY; COCAINE DEPENDENCE; EOSINOPHIL; FORENSIC TOXICOLOGY; HAIR; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIVER; MALE; MASS SPECTROMETRY; PATHOLOGY; VITREOUS BODY;

ASTHMA; BILE; BRONCHI; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COCAINE-RELATED DISORDERS; DESIGNER DRUGS; EOSINOPHILS; FORENSIC TOXICOLOGY; HAIR; HUMANS; LIVER; MALE; MASS SPECTROMETRY; PIPERAZINES; SEROTONIN RECEPTOR AGONISTS; VITREOUS BODY; YOUNG ADULT;

EID: 84872401010     PISSN: 00221198     EISSN: 15564029     Source Type: Journal    
DOI: 10.1111/j.1556-4029.2012.02254.x     Document Type: Article

References (26)

1. European Police Office. Europol-EMCDDA active monitoring report on a new psychoactive substance: 1-(3-chlorophenyl)piperazine (mCPP): Annex 3: legal status. European Monitoring Center on Drugs and Drug Addiction, 2008, http://www.emcdda.europa.eu/html.cfm/index16775EN.html (accessed January 12, 2009).
2. Lecompte Y, Evrard I, Arditti J. La métachlorophénylpipérazine (mCPP): une nouvelle drogue de synthèse. Therapie 2006;61:523-30.
3. M-chlorophénylpipérazine (mCPP): identifications répé;tées et malaises. Note d'information du 17 février 2006. Saint Denis, France: Observatoire Français des Drogues et des Toxicomanies, 2006.
4. M-chlorophénylpipérazine (mCPP): nouvelle identification. Note d'information du 14 mars 2006. Saint Denis, France: Observatoire Français des Drogues et Toxicomanies, 2006.
5. Baumann MH, Ayestas MA, Dersch CM, Rothman RB. 1-(m-Chlorophenyl)piperazine (mCPP) dissociates in vivo serotonin release from long-term serotonin depletion in rat brain. Neuropsychopharmacology 2001;5:492-501.
6. Bossong MG, Van Dijk JP, Niesink RJM. Methylone and mCPP, two new drugs of abuse? Addict Biol 2005;10:321-3.
7. European Police Office. Europol-EMCDDA joint report on a new psychoactive substance: 1-(3-chlorophenyl)piperazine (mCPP). European Monitoring Center on Drugs and Drug Addiction, 2005, www.emcdda.europa.eu/attachements.cfm/att_33256_EN_Final_Europol-EMCDDA_Active_Monitoring_Report_mCPP_290307.pdf (accessed January 12, 2009).
8. Baumann MH, Clark RD, Budzynski AG, Partilla JS, Blough BE, Rothman RB. N-substituted piperazines abused by humans mimic the molecular mechanism of 3, 4-methylenedioxymethamphetamine (MDMA, or "Ecstasy"). Neuropsychopharmacology 2005;30:550-60.
9. Tancer ME, Johanson CE. The subjective effects of MDMA and mCPP in moderate MDMA users. Drug Alcohol Depend 2001;65:97-101.
10. Staack RF. Piperazine designer drugs of abuse. Lancet 2007;369:1411-3.
11. Tancer M, Johanson CE. Reinforcing, subjective, and physiological effects of MDMA in humans: a comparison with d-amphetamine and m-CPP. Drug Alcohol Depend 2003;72:33-44.
12. Kast RE. Are we done with trazodone? The potential for damage by mCPP a metabolite of trazodone. Acta Neuropsychiatr 2007;19:220-1.
13. Staack RF, Paul LD, Schmid D, Roider G, Rolf B. Proof of a 1-(3-chlorophenyl)piperazine (mCPP) intake: use as adulterant of cocaine resulting in drug-drug interactions? J Chromatogr B Analyt Technol Biomed Life Sci 2007;855:127-33.
14. Chatenay C, Bévalot F, Mounier C, Gaillard Y, Grelaud G, Prévosto JM. Systematic toxicological screening analysis using UPLC/UV/MS. Proceedings of the 47th Annual Meeting of The International Association of Forensic Toxicologists; 2007 Aug 23-27; Geneva, Switzerland. Annales de Toxicologie Analytique ATA 2009;21(1):S1-101 (ISSN 0768 - 598X).
15. Gaillard Y, Pépin G. Screening and identification of drugs in human hair by high-performance liquid chromatography-photodiode array detection and gas chromatography-mass spectrometry after solid phase extraction. A powerful tool in forensic medicine. J Chromatogr A 1997;762:251-67.
16. Gaillard Y, Pépin G. Testing hair for pharmaceuticals. J Chromatogr B 1999;773:231-46.
17. Society of Hair Testing. Consensus on hair testing. Forensic Sci Int 1997;84(1):3-6.
18. Society of Hair Testing. Recommendation for hair testing in forensic cases. Forensic Sci Int 2004;83:145.
19. Kronstrand R, Scott K. Drug incorporation into hair. In: Kintz P, editor. Analytical and practical aspects of drug testing in hair. Boca Raton, FL: Taylor & Francis, 2006;1-23.
20. Anger JP, Paysant F, Lichtmann A, Raffault R, Dumestre-Toulet V, Pépin G, et al. La thanathopraxie: une technique utile pour conserver les corps, mais qui peut gêner l'expertise toxicologique médico-légale. Ann Toxicol Anal 2008;20:1-10.
21. Kovaleva J, Devuyst E, De Paepe P, Verstraete A. Acute chlorophenylpiperazine overdose: a case report and review of the literature. Ther Drug Monit 2008;30:394-8.
22. Peters FT, Schaefer S, Staack RF, Kraemer T, Maurer HH. Screening for and validated quantification of amphetamine- and piperazine-derived designer drugs in human blood plasma by gas chromatography/mass spectrometry. J Mass Spectrum 2003;38:659-76.
23. Patel BN, Sharma N, Sanyal M, Shrivastav PS. High throughput and sensitive determination of trazodone and its primary metabolite, m-chlorophenylpiperazine, in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2008;871:44-54.
24. Ohkubo T, Osanai T, Sugawar K, Ishida M, Otani K, Mihara K, et al. High-performance liquid chromatographic determination of trazodone and 1-m-chlorophenylpiperazine with ultraviolet and electrochemical detector. J Pharm Pharmacol 1995;47:340-4.
25. Vatassery GT, Holden LA, Hazel DK, Dysken MH. Determination of trazodone and its metabolite 1-m-chlorophenyl-piperazine, in human plasma and red blood cell samples by HPLC. Clin Biochem 1997;30:149-53.
26. Mercolini L, Colliva C, Amore M, Fanali S, Raggi RA. HPLC analysis of the antidepressant trazodone and its main metabolite m-CPP in human plasma. J Pharm Biomed Anal 2008;47:882-7.